Comparison of thrice-daily lispro 50/50 vs thrice-daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes

6Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aims/Introduction: Basal-bolus intensive insulin therapy has been believed to achieve best the glycemic control, but is also complicated as a result of the number of injections required and the type of insulin. This study compared the effect of thrice-daily lispro 50/50 (prandial premixed therapy [PPT]) with thrice daily lispro given in combination with sulfonylureas (prandial bolus therapy with sulfonylurea [PBTS]) as initial insulin therapy for type 2 diabetes. Materials and Methods: This 24-week, observational, parallel trial comprised a 12-week screening period and a 24-week intervention period for 31 diabetes patients who were poorly controlled with submaximal sulfonylurea. At the start of the intervention period, we commenced thrice-daily insulin injections and divided the 31 patients into either lispro 50/50 with discontinuation of sulfonylurea (PPT, n = 15) or lispro added to sulfonylurea (PBTS, n = 16). The same dose-adjustment algorithm was used for analyzing both groups; HbA1c, plasma glucose, insulin daily dose, bodyweight and number of hypoglycemic episodes were evaluated. Results: At the end of the study, HbA1c was significantly improved in both groups (P < 0.00001), but no difference was apparent between the groups. The daily doses of PPT were more than those of PBTS, albeit the difference was statistically insignificant (P = 0.051). There were significantly fewer hypoglycemic episodes encountered with PPT than with PBTS. Conclusions: Thrice-daily injections of lispro 50/50 provide an effective and safe regimen as initial insulin therapy for type 2 diabetes. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2010.00025.x, 2010). © 2010 Asian Association for the Study of Diabetes and Blackwell Publishing Asia Pty Ltd.

References Powered by Scopus

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49)

2236Citations
N/AReaders
Get full text

The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

1444Citations
N/AReaders
Get full text

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American diabetes association and the European association for the study of diabetes

1124Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Use of 50/50 Premixed Insulin Analogs in Type 2 Diabetes: Systematic Review and Clinical Recommendations

9Citations
N/AReaders
Get full text

Efficacy and safety of biphasic insulin aspart and biphasic insulin lispro mix in patients with type 2 diabetes: A review of the literature

6Citations
N/AReaders
Get full text

A novel option for prandial insulin therapy: inhaled insulin

4Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Yamashiro, K., Ikeda, F., Fujitani, Y., Watada, H., Kawamori, R., & Hirose, T. (2010). Comparison of thrice-daily lispro 50/50 vs thrice-daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes. Journal of Diabetes Investigation, 1(4), 149–153. https://doi.org/10.1111/j.2040-1124.2010.00025.x

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 8

73%

Researcher 2

18%

Professor / Associate Prof. 1

9%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

64%

Psychology 2

18%

Agricultural and Biological Sciences 1

9%

Nursing and Health Professions 1

9%

Save time finding and organizing research with Mendeley

Sign up for free